Epidermal growth factor receptor (EGFR) is expressed in 50% of NSCLCs, and its expression is correlated with poor prognosis. These two factors make EGFR and its family members prime candidates for ...
DM Intelligence Medicine Ltd. has disclosed leucine-rich repeat kinase 2 (LRRK2; dardarin), LRRK2 (G2019S mutant) and/or EGFR (HER1; erbB1 mutant) inhibitors reported to be useful for the treatment of ...
Future Oncol. 2011;7(12):1441-1450. Several Phase II studies have investigated the humanized monoclonal, anti-EGFR antibody cetuximab in gastric cancer. These studies, summarized in Table 3 ...